Patients with cystic fibrosis (CF) who were treated with ivacaftor have demonstrated favorable results for clinically important outcomes, including a lower prevalence of CF-related complications and improved lung function, according to a new study.
Patients with cystic fibrosis (CF) who were treated with ivacaftor have demonstrated favorable results for clinically important outcomes, including a lower prevalence of CF-related complications and improved lung function, according to a new study.
The study, published in Thorax, assessed the clinical outcomes and disease progression in ivacaftor-treated patients using data from the US and United Kingdom (UK) CF registries. Ivacaftor was described as the first CF transmembrane conductance regulator (CFTR) modulator that demonstrated clinical benefits in patients with CF.
“Ivacaftor is intended for chronic, lifelong use. Therefore, understanding the long-term effects of therapy is important for patients, caregivers, healthcare providers, payers and regulators,” the authors said. “Furthermore, since the therapy addresses the underlying cause of CF, long-term data are complementary to data from the clinical development programs.”
The researchers collected data from the US CF Foundation Patient Registry (US CFFPR) and the UK CF Registry (UK CFR) to compare ivacaftor-treated and untreated matched comparator patients for risks of death, transplantation, hospitalization, pulmonary exacerbation, prevalence of CF-related complications, and microorganism and lung function changes.
A total of 1256 ivacaftor-treated patients and 6200 comparator patients from the US were included, while 411 ivacaftor-treated and 2069 comparator patients from the UK were included in the analysis. According to the safety evaluations, ivacaftor-treated US patients had significantly lower risks of death, transplantation, hospitalization, and pulmonary exacerbation relative to comparators. The results and trends were similar in the UK.
“We aimed to monitor patients treated with ivacaftor for any potential new safety concerns via evaluation of important clinical outcomes captured in the national CF registries in the [United States] and UK,” explained the authors. “The analyses also allowed to further assess if the effects of ivacaftor on long-term clinical outcomes, including mortality, are consistent with data supporting the disease modification potential for CFTR modulator therapy.”
Additionally, in both of the registries, ivacaftor-treated patients had a lower prevalence of CF-related complications and select microorganisms, and had more greatly improved lung function.
“Data from [2] large independent national CF patient registries evaluated in this study revealed consistently favorable findings with respect to clinically important outcomes among ivacaftor-treated patients, adding to the literature on the effects of ivacaftor therapy,” the study said.
The authors acknowledged the potential limitations of the analysis because of the observational research that lacks scheduled visits and standardized assessments, with no specific dates of therapy initiation. However, since the study represented such a large analysis, the results can be relevant to the broader CF population.
Reference
Bessonova L, Volkova N, Higgins M, et al. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. [Published online May 10, 2018.] Thorax. doi:10.1136/thoraxjnl-2017-210394.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More